EyePoint Pharmaceuticals (the “Company” or “EyePoint”) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery, including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, for the treatment of postoperative inflammation following ocular surgery.